Zydus Lifesciences Completes Acquisition of Agenus Biologics Manufacturing Facilities, Launches Zylidac Bio LLC in the U.S.
Zydus Lifesciences Limited, an innovation-led life-sciences company, has successfully closed the acquisition of Agenus Inc.’s biologics manufacturing facilities in the U.S. The acquired manufacturing assets and operations will be housed under a newly formed subsidiary named Zylidac Bio LLC. This deal supports the evolving landscape of biological product manufacturing in the U.S., providing a localized supply chain for global innovators and securing dedicated, high-quality U.S. biologics capacity to support botensilimab and balstilimab. The launch of Zylidac Bio LLC is significant in light of the BIOSECURE Act, providing a ‘safe-harbor’ for global biopharmaceutical companies seeking to transition their supply chains to compliant, U.S.-based partners.
Key Highlights
- Zydus Lifesciences completes the acquisition of Agenus Inc.’s biologics manufacturing facilities.
- The acquisition establishes Zydus’ advanced manufacturing facilities in the global biologics contract development and manufacturing organization (CDMO) business.
- Zylidac Bio LLC offers a critical, compliant solution for global innovators and allows for a localized supply chain.
- The deal supports the evolving landscape of biological product manufacturing in the U.S., prioritizing secure, domestic, and high-quality supply chains for advanced therapies.
- Zylidac Bio LLC provides a ‘safe-harbor’ for global biopharmaceutical companies seeking to transition their supply chains to compliant, U.S.-based partners.